T. Rowe Price Associates
BIO icon

T. Rowe Price Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

T. Rowe Price Associates’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.7M Sell
74,281
-1,990
-3% -$573K ﹤0.01% 1027
2025
Q4 		$23.1M Buy
76,271
+794
+1% +$248K ﹤0.01% 1030
2025
Q3 		$21.2M Buy
75,477
+38,654
+105% +$10.5M ﹤0.01% 1046
2025
Q2 		$8.89M Buy
36,823
+7,348
+25% +$1.74M ﹤0.01% 1134
2025
Q1 		$7.18M Buy
29,475
+331
+1% +$99.6K ﹤0.01% 1177
2024
Q4 		$9.57M Buy
29,144
+1,524
+6% +$517K ﹤0.01% 1164
2024
Q3 		$9.24M Sell
27,620
-17,730
-39% -$5.63M ﹤0.01% 1152
2024
Q2 		$12.4M Buy
45,350
+768
+2% +$223K ﹤0.01% 1070
2024
Q1 		$15.4M Buy
44,582
+748
+2% +$246K ﹤0.01% 1034
2023
Q4 		$14.2M Sell
43,834
-2,113
-5% -$662K ﹤0.01% 1032
2023
Q3 		$16.5M Sell
45,947
-5,175
-10% -$2M ﹤0.01% 962
2023
Q2 		$19.4M Sell
51,122
-350
-0.7% -$142K ﹤0.01% 945
2023
Q1 		$24.7M Sell
51,472
-4,356
-8% -$2.04M ﹤0.01% 865
2022
Q4 		$23.5M Sell
55,828
-11,450
-17% -$4.62M ﹤0.01% 865
2022
Q3 		$28.1M Buy
67,278
+339
+0.5% +$169K ﹤0.01% 807
2022
Q2 		$33.1M Sell
66,939
-3,445
-5% -$1.79M ﹤0.01% 1011
2022
Q1 		$39.6M Sell
70,384
-3,073
-4% -$1.85M ﹤0.01% 1050
2021
Q4 		$55.5M Sell
73,457
-749
-1% -$561K 0.01% 963
2021
Q3 		$55.4M Sell
74,206
-7,785
-9% -$5.83M 0.01% 971
2021
Q2 		$52.8M Buy
81,991
+9,321
+13% +$5.67M ﹤0.01% 1006
2021
Q1 		$41.5M Buy
72,670
+36,163
+99% +$21.4M ﹤0.01% 1067
2020
Q4 		$21.3M Sell
36,507
-56,411
-61% -$32.1M ﹤0.01% 1215
2020
Q3 		$47.9M Sell
92,918
-19,413
-17% -$9.83M 0.01% 886
2020
Q2 		$50.7M Sell
112,331
-43,405
-28% -$19.2M 0.01% 850
2020
Q1 		$54.6M Buy
155,736
+529
+0.3% +$195K 0.01% 754
2019
Q4 		$57.4M Buy
155,207
+238
+0.2% +$83.9K 0.01% 867
2019
Q3 		$51.6M Sell
154,969
-2,172
-1% -$709K 0.01% 864
2019
Q2 		$49.1M Sell
157,141
-860
-0.5% -$258K 0.01% 901
2019
Q1 		$48.3M Sell
158,001
-1,886
-1% -$509K 0.01% 893
2018
Q4 		$37.1M Buy
159,887
+8,983
+6% +$2.41M 0.01% 934
2018
Q3 		$47.2M Buy
150,904
+6,065
+4% +$1.88M 0.01% 935
2018
Q2 		$41.8M Buy
144,839
+5,690
+4% +$1.57M 0.01% 957
2018
Q1 		$34.8M Buy
139,149
+253
+0.2% +$64.4K 0.01% 1000
2017
Q4 		$33.1M Buy
138,896
+1,145
+0.8% +$277K 0.01% 1022
2017
Q3 		$30.6M Buy
137,751
+8,352
+6% +$1.88M 0.01% 1037
2017
Q2 		$29.3M Sell
129,399
-1,975
-2% -$430K 0.01% 1030
2017
Q1 		$26.2M Buy
131,374
+15,235
+13% +$2.93M ﹤0.01% 1053
2016
Q4 		$21.2M Sell
116,139
-2,898
-2% -$494K ﹤0.01% 1122
2016
Q3 		$19.5M Buy
119,037
+4,800
+4% +$729K ﹤0.01% 1140
2016
Q2 		$16.3M Sell
114,237
-1,515
-1% -$216K ﹤0.01% 1158
2016
Q1 		$15.8M Sell
115,752
-6,080
-5% -$798K ﹤0.01% 1155
2015
Q4 		$16.9M Buy
121,832
+8,242
+7% +$1.14M ﹤0.01% 1136
2015
Q3 		$15.3M Buy
113,590
+23,100
+26% +$3.32M ﹤0.01% 1180
2015
Q2 		$13.6M Buy
90,490
+38,900
+75% +$5.57M ﹤0.01% 1258
2015
Q1 		$6.97M Buy
51,590
+4,300
+9% +$533K ﹤0.01% 1419
2014
Q4 		$5.7M Sell
47,290
-3,400
-7% -$391K ﹤0.01% 1440
2014
Q3 		$5.75M Hold
50,690
– – ﹤0.01% 1432
2014
Q2 		$6.07M Buy
50,690
+2,400
+5% +$293K ﹤0.01% 1424
2014
Q1 		$6.19M Sell
48,290
-200
-0.4% -$25.6K ﹤0.01% 1397
2013
Q4 		$5.99M Sell
48,490
-600
-1% -$73.1K ﹤0.01% 1403
2013
Q3 		$5.77M Sell
49,090
-600
-1% -$70.8K ﹤0.01% 1397
2013
Q2 		$5.58M Buy
+49,690
New +$5.83M ﹤0.01% 1387

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's BIO Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.6% in Q1 2026, selling an estimated $573K and leaving 74,281 shares worth $20.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1027.

T. Rowe Price Associates first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $57.4M in Q4 2019. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • T. Rowe Price Associates held 74,281 shares of Bio-Rad Laboratories Class A worth $20.7M as of Q1 2026.
  • T. Rowe Price Associates sold 1,990 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $573K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1027 holding.
  • T. Rowe Price Associates first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Bio-Rad Laboratories Class A position peaked at $57.4M in Q4 2019.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.